| __timestamp | Alnylam Pharmaceuticals, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 72471000 |
| Thursday, January 1, 2015 | 60610000 | 89204000 |
| Friday, January 1, 2016 | 89354000 | 106010000 |
| Sunday, January 1, 2017 | 199365000 | 137905000 |
| Monday, January 1, 2018 | 382359000 | 159888000 |
| Tuesday, January 1, 2019 | 479005000 | 158425000 |
| Wednesday, January 1, 2020 | 588420000 | 200677000 |
| Friday, January 1, 2021 | 620639000 | 304759000 |
| Saturday, January 1, 2022 | 770658000 | 377221000 |
| Sunday, January 1, 2023 | 795646000 | 336361000 |
| Monday, January 1, 2024 | 975526000 |
Data in motion
In the competitive world of biopharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability and growth. Alnylam Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. have shown distinct trajectories in their SG&A spending from 2014 to 2023.
Alnylam's SG&A expenses surged by over 1,600% during this period, reflecting its aggressive expansion and investment in market presence. In contrast, Supernus exhibited a more conservative growth of approximately 360%, indicating a steady, controlled approach to scaling operations.
By 2023, Alnylam's SG&A expenses were more than double those of Supernus, highlighting its commitment to rapid growth. This comparison underscores the diverse strategies employed by biopharma companies in navigating market challenges and opportunities. Understanding these trends offers valuable insights into the financial strategies that drive success in the pharmaceutical industry.
Cost Management Insights: SG&A Expenses for Merck & Co., Inc. and Alnylam Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? GSK plc or Supernus Pharmaceuticals, Inc.
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Pharming Group N.V. Trends and Insights
Alnylam Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Dynavax Technologies Corporation Trends and Insights
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Novavax, Inc.
Breaking Down SG&A Expenses: Bio-Techne Corporation vs Supernus Pharmaceuticals, Inc.
Comparing SG&A Expenses: Catalent, Inc. vs Supernus Pharmaceuticals, Inc. Trends and Insights
Grifols, S.A. or Supernus Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: ACADIA Pharmaceuticals Inc. vs Supernus Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Merus N.V. and Supernus Pharmaceuticals, Inc.
HUTCHMED (China) Limited vs Supernus Pharmaceuticals, Inc.: SG&A Expense Trends